{"organizations": [], "uuid": "002816a8ad2e73ee71e365ccaea3612075187bfe", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shire-sells-oncology-business-to-s/brief-shire-sells-oncology-business-to-servier-for-2-4-billion-idUSFWN1RT04K", "country": "US", "domain_rank": 408, "title": "BRIEF-Shire Sells Oncology Business To Servier For $2.4 Billion", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.038, "site_type": "news", "published": "2018-04-16T14:46:00.000+03:00", "replies_count": 0, "uuid": "002816a8ad2e73ee71e365ccaea3612075187bfe"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shire-sells-oncology-business-to-s/brief-shire-sells-oncology-business-to-servier-for-2-4-billion-idUSFWN1RT04K", "ord_in_thread": 0, "title": "BRIEF-Shire Sells Oncology Business To Servier For $2.4 Billion", "locations": [], "entities": {"persons": [{"name": "shire", "sentiment": "none"}], "locations": [], "organizations": [{"name": "shire plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "servier", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Shire PLC:\n* SHIRE ANNOUNCES SALE OF ONCOLOGY BUSINESS TO SERVIER FOR $2.4 BILLION\n* PORTFOLIO ALSO INCLUDES CALASPARGASE PEGOL (CAL-PEG)\n* SERVIER HAS AGREED TO ACQUIRE SHIRE’S ONCOLOGY BUSINESS AND PAY TOTAL CONSIDERATION IN CASH, UPON COMPLETION\n* TRANSACTION HAS BEEN APPROVED BY BOARD OF DIRECTORS AND IS EXPECTED TO CLOSE IN SECOND OR Q3 OF 2018\n* PROCEEDS FROM TRANSACTION INCREASE OPTIONALITY AND BOARD WILL CONSIDER RETURNING PROCEEDS OF SALE TO SHAREHOLDERS THROUGH SHAREHOLDER-APPROVED SHARE BUYBACK AFTER CURRENT OFFER PERIOD\n* DEAL COVERS TRANSFER OF SHIRE’S ONCOLOGY BUSINESS INCLUDING IN-MARKET PRODUCTS ONCASPAR , EX-U.S. RIGHTS TO ONIVYDE Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T14:46:00.000+03:00", "crawled": "2018-04-17T12:26:57.010+03:00", "highlightTitle": ""}